welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
Parent Project Muscular Dystrophy Designates Children’s Hospital of Wisconsin a Certified Duchenne Care Center
Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), named the Neuromuscular Disorders Program at Children’s Hospital of Wisconsin to be the 21st clinic to be named a Certified Duchenne Care Center, a designation created in 2014 as part of the organization’s Certified Duchenne Care Center Program.
Duchenne is the most common fatal genetic disorder diagnosed in childhood, affecting approximately one in 5,000 live male births.
rareRelated
-
A Phase 3 Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids, in Ambulatory Subj...To evaluate the efficacy and safety of p...
-
Capricor trial failure in heart disease might offer another opportunityOn Friday Capricor Therapeutics announce...
-
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular DystrophyThe main purpose of this study is to tes...
-
Avidity Biosciences Receives Investment from CureDuchenneAvidity Biosciences, a privately held bi...
-
A Pharmacokinetic Study of Oral Deflazacort in Children and Adolescent Subjects With Duchenne Muscular DystrophyStudy to characterize the single-state a...
-
Exploratory Study of NS-065/NCNP-01 in DMDThis study is designed to assess the saf...
-
Safety, Tolerability, and Pharmacokinetics of SMT C1100, a 2-Arylbenzoxazole Utrophin Modulator, following Single- a...Purpose: SMT C1100 is a utrophin modula...
-
A New Era in the Management of Duchenne Muscular DystrophyThe management of Duchenne muscular dyst...
-
MoveDMD: phase 2 trial of edasalonexent, an NF-κB inhibitor, in 4 to 7-year old patients with Duchenne muscular dys...NF-κB is activated from infancy in DMD,...
